<DOC>
	<DOCNO>NCT00618696</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody block cancer growth different way . Some block ability cancer cell grow spread . Radioactive monoclonal antibody , yttrium Y 90 monoclonal antibody , find cancer cell either kill carry cancer-killing substance without harm normal cell . PURPOSE : This phase I trial study side effect best dose yttrium Y 90 monoclonal antibody much radiation take organ body treat patient advanced leukemia hematologic disorder .</brief_summary>
	<brief_title>Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 Treating Patients With Advanced Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish dose 150 mg/m² nonradiolabeled anti-CD45 monoclonal antibody AHN-12 result normal biodistribution , normal-organ estimate radiation-absorbed dose less 20 Gy , estimate radiation-absorbed dose 13 Gy red marrow . Secondary - To determine maximum tolerate dose yttrium Y 90 anti-CD45 monoclonal antibody AHN-12 ( ^90Y-AHN-12 ) . - To determine human anti-mouse antibody ( HAMA ) response . - To define , preliminarily , antitumor activity ^90Y-AHN-12 . OUTLINE : This dose-escalation study yttrium Y 90 anti-CD45 monoclonal antibody AHN-12 ( ^90Y-AHN-12 ) . - Biodistribution : Patients receive nonradiolabeled monoclonal antibody AHN-12 IV image dose indium Y 111 monoclonal antibody AHN-12 ( ^111In-AHN-12 ) IV 10 minute day 0 . Patients undergo whole-body gamma-camera image immediately follow infusion , 4-6 hour , day 1 , 3 , 4 , 7 . Blood sample collect prior image dosimetry calculation pharmacokinetics . Patients also undergo bone marrow biopsy 16-24 hour infusion dosimetry calculation . Patients expected biodistribution ^111In-AHN-12 , estimate radiation-absorbed dose normal organ &lt; 20 Gy , estimate radiation-absorbed dose red marrow ≤ 13 Gy , negative human anti-mouse antibody day 7 proceed therapy portion . - Treatment : Patients receive nonradiolabeled anti-CD45 monoclonal antibody AHN-12 IV 60 minute escalate therapy dose yttrium Y 90 anti-CD45 monoclonal antibody AHN-12 ( ^90Y-AHN-12 ) IV 10 minute day 7 8 . After completion study treatment , patient follow periodically 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm CD45+ disease : Acute lymphoblastic leukemia acute myeloid leukemia ( AML ) , meet follow criterion : Primary refractory disease Relapsed disease , define persistent disease follow minimum 2 different standard chemotherapy induction attempt time diagnosis relapse Acute myelogenous leukemia ( AML ) , primary refractory relapse disease define persistent disease minimum two different standard chemotherapy induction attempt time diagnosis relapse Advanced myelodysplastic syndrome ( MDS ) define &gt; = 15 % bone marrow blast follow minimum one standard chemotherapy induction attempt AML arise preexist MDS , refractory define persistent disease follow minimum one standard chemotherapy induction attempt Chronic myelogenous leukemia ( CML ) follow blast crisis ( &gt; = 15 % marrow blast follow minimum one standard chemotherapy induction attempt Peripheral leukemic blast ( morphology ) must &lt; 5,000/μL ( hydroxyurea control peripheral blast count allow ) Must source allogeneic stem cell ( sibling , unrelated cord [ ] , donor ) identify prior initiation protocol therapy Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 02 Karnofsky PS 60100 % Life expectancy &gt; 12 week Total bilirubin ≤ 2.5 time upper limit normal ( ULN ) aspartate aminotransferase ( AST ) Alanine transaminase ( ALT ) ≤ 2.5 time upper limit normal ( ULN ) Creatinine ≤ 1.3 mg/dL OR creatinine clearance ≥ 60 mL/min Left ventricular ejection fraction ( LVEF ) ≥ 45 % Multi Gated Acquisition Scan ( MUGA ) echocardiogram ( ECHO ) Carbon Monoxide Diffusing Capacity ( DLCO ) ( correct ) ≥ 50 % predict Human antimouse antibody ( HAMA ) must negative Not pregnant nursing Fertile patient must use effective contraception Human immunodeficiency virus ( HIV ) negative Recovered prior therapy At least 7 day since prior biologic agent Bone marrow cellularity &lt; 15 % Known brain metastasis active central nervous system ( CNS ) disease History allergic reaction attribute compound similar chemical biologic composition ^90YAHN12 agent use study Uncontrolled illness , include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement Other concurrent investigational agent Prior allogeneic transplantation Less 60 day since prior autologous transplantation relapse disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>